Cost-effectiveness of adjuvant interferon therapy after surgical resection of hepatitis C-related hepatocellular carcinoma

Liver

Volumn 22, Issue 6, 2002, Pages 479-485

  Hoshida, Yujin ^a   Shiratori, Yasushi ^a   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cost effectiveness; Cost effectiveness ratio inferon; Hepatitis C; Hepatocellular carcinoma; Incremental; Interferon; Markov model; Surgical resection

Indexed keywords

INTERFERON;

ADJUVANT THERAPY; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CASE REPORT; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; DRUG RESPONSE; HEPATITIS C; HUMAN; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MALE; STATISTICAL MODEL;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; HEPATITIS C; HUMANS; INTERFERONS; LIFE EXPECTANCY; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MARKOV CHAINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL;

EID: 0036905052     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0676.2002.01736.x     Document Type: Article

References (78)

1. TAYLOR-ROIBINSON S D, FOSTER G R, ARORA S, HARGREAVES S, THOMAS H C. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997; 350: 1142-3.
2. DEUFFIC S, POYNARD T, BUFFAT L, VALLERON A J. Trends in primary liver cancer. Lancet 1998; 351: 214-5.
3. EL-SERAG H B, MASON A C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50.
4. OKUDA K. Epidemiology. In: LIVRAGHI T, MAKUUCHI M, BUSCARINI L, eds. Diagnosis and treatment of hepatocellular carcinoma. London: Greenwich Medical Media, 1997; 3-16.
5. LLOVET J M, BUSTAMANTE J, CASTELLS A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma. Rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29: 62-7.
6. LLOVET J M, FUSTER J, BRUIX J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 1434-40.
7. SARASIN F P, GIOSTRA E, MENTHA G, HADENGUE A. Partial hepatectomy or orthotopic liver transplantation for the treatment of resectable hepatocellular carcinoma. A cost-effectiveness perspective. Hepatology 1998; 28: 436-42.
8. MANJO P E, SARASIN F P, MENTHA G, HADENGUE A. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small heptocellular carcinoma and preserved liver function: an outcome-oriented decision analysis. Hepatology 2000; 31: 899-906.
9. BENNETT W G, INOUE Y, BECK R, WONG J B, PAUKER S G, DAVIS G L. Estimates of cost-effectiveness of a single course of interferon-α2b in patients with histologically mild hepatitis C. Ann Intern Med 1997; 127: 855-65.
10. KIM W R, POTERUCHA J J, HERMANS J E, et al. Cost-effectiveness of 6 and 12 months of interferon-α therapy for chronic hepatitis C. Ann Intern Med 1997; 127: 866-74.
11. YOUNOSSI Z M, SINGER M E, MCHUTCHISON J G, SHERMOCK K M. Cost-effectiveness of interferon α2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999; 30: 1318-24.
12. POYNARD T, LEROY V, COHARD M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C effects of dose and duration. Hepatology 1996; 24: 778-89.
13. THEVENOT T, REGIMBEAU C, RATZIU V, LEROY V, OPOLON P, POYNARD T. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update. J Viral Hepat 2001; 8: 48-62.
14. NISHIGUCHI S, KUROKI T, NAKATANI S, et al. Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
15. SHIRATORI Y, IMAZEKI F, MORIYAMA M, et al. Histologic improvement of fibrosis in hepatitis C patients with sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-24.
16. IKEDA K, SAITOH S, ARASE Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C. A long-term observation study of 1, 643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124-30.
17. IKEDA K, ARASE Y, SAITOH S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000; 32: 228-32.
18. KUBO S, NISHIGUCHI S, HIROHASHI K, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001; 134: 963-7.
19. MUTO Y, MORIWAKI H, NINOMIYA M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996; 334: 1561-7.
20. LAU W Y, LEUNG T W T, HO S K W, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999; 353: 797-801.
21. TAKAYAMA T, SEKINE T, MAKUUCHI M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial. Lancet 2000; 356: 802-7.
22. SONNENBERG F A, BECK J R. Markov modes in medical decision making: a practical guide. Med Decis Making 1993; 13: 332-8.
23. PETITTI D B. Meta-Analysis, Decision-Analysis and Cost-Effectiveness Analysis, 2nd edn. New York: Oxford University Press, 2000.
24. ANDERSON R N. United States Life Table, 1998. National Vital Statistics Reports, Vol. 48. No. 18. Hyattsville. Maryland: National Center for Health Statistics, 2001.
25. FATTOVICH G, GIUSTINA G, DEGOS F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72.
26. GINES P, QUINTERO E, ARROYO V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7: 122-8.
27. D'AMICO G, MORABITO A, PAGLIARO L, MARUBINI E and the Liver Study Group of 'V' Cervello' Hospital. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986; 31: 468-75.
28. SCHLICHTING P, CHRISTENSEN E, ANDERSEN P K, FAUERHOLDT L, JUHL E, POULSEN H and the Copenhagen Study Group for Liver Diseases. Prognostic factors in cirrhosis identified by Cox's regression model. Hepatology 1983; 3: 889-95.
29. CHRISTENSEN E, SCHLICHTING P, FAUERHOLDT L, GLUUD C, ANDERSEN P K, JUHL E and the Copenhagen Study Group for Liver Diseases. Prognostic value of Child-Turcotte Criteria in medically treated cirrhosis. Hepatology 1984; 4: 430-5.
30. FUSTER J, GARCIA-VALDECASAS J C, GRANDE L, et al. Hepatocellular carcinoma and cirrhosis. Results of surgical treatment in a European series. Ann Surg 1996; 223: 297-302.
31. FARMER D G, ROSOVE M H, SHAKED A, BUSUTTIL R W. Current treatment modalities for hepatocellular carcinoma. Ann Surg 1994; 219: 236-47.
32. BELGHITI J. Resection of hepatocellular carcinoma complicating cirrhosis. Br J Surg 1991; 78: 257-8.
33. CALVET X, BRUIX J, GINES P, et al. Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology 1990; 12: 753-60.
34. CHEN M F, JENG L B, LEE W C, CHEN T C. Surgical results in patients with dual hepatitis B- and C-related hepatocellular carcinoma compared with hepatitis B- or C-related hepatocellular carcinoma. Surgery 1998; 123: 5514-9.
35. KUMADA T, NAKANO S, TAKEDA I, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997; 25: 87-92.
36. POON R T P, FAN S T, LO C M, LIU C L, WONG J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma. Ann Surg 1999; 229: 216-22.
37. IKEDA K, SAITOH S, TSUBOTA A, et al. Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer 1993; 71: 19-25.
38. LLOVET J M, FUSTER J, BRUIX J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 1434-40.
39. UNOS and the Division of Organ Transplantation, Health Resources and Service Administration, 1994 Center Specific Report. liver data. UNOS Update 1995; 11: 15-8.
40. GANE E J, PORTMANN B C, NAOUMOV N V, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-20.
41. ASCHER N L, LAKE J R, EMOND J, ROBERTS J. Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology 1994; 20: 24S-27S.
42. DETRE K M, BELLE SH, LOMBARDDERO M. Liver transplantation for chronic viral hepatitis. Viral Hepatitis Rev 1996; 2: 219-28.
43. KILPE V E, KRAKAUER H, WREN R E. An analysis of liver transplant experience from 37 transplant centers as reported to Medicare. Transplantation 1993; 56: 554-61.
44. MAJNO P E, ADAM R, BISMUTH H, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997; 226: 688-701.
45. MAZZAFFERRO V, REGALIA E, DOCI R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
46. BISMUTH H, CHICHE L, ADAM R, CASTAING D, DIAMOND T, DENNISON A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993; 218: 145-51.
47. MARSH J W, DVORCHIK I, SUBOTIN M, et al. The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology 1997; 26: 444-50.
48. FIGUERAS J, JAURRIETA E, VALLS C, et al. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study. Hepatology 1997; 25: 1485-9.
49. OTTO G, HEUSCHEN U, HOFMANN W J, KRUMM G, HINZ U, HERFARTH C. Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: a retrospective analysis. Ann Surg 1998; 227: 424-32.
50. BECK J R, PAUKER S G, GOTTLIEB J E, KLEIN K, KASSIRER J P. A convenient approximation of life expectancy (The 'DEALE') II. Use in medical decision-making. Am J Med 1982; 73: 889-97.
51. VALLA D C, CHEVALLIER M, MARCELLIN P, et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon-alfa-2b versus no treatment. Hepatology 1999; 29: 1870-5.
52. SHIRATORI Y, YOKOSUKA O, NAKATA R, et al. Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA. Hepatology 1999; 29: 1573-80.
53. SCHALM S W, WEILAND O, HANSEN B E, et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis Gastroenterol 1999; 117: 408-13.
54. ASCIONE A, DE LUCA M, CANESTRINI C, et al. Efficacy of high dose of recombinant alpha 2b interferon on long term response in chronic hepatitis C and cirrhosis: prospective randomized multicentre study. Ital J Gastroenterol Hepatol 1998; 30: 517-23.
55. TANAKA K, SATA M, UCHIMURA Y, SUZUKI H, TANIKAWA K. Long-term evaluation of interferon therapy in hepatitis C virus-associated cirrhosis: does IFN prevent development of hepatocellular carcinoma? Oncol Report 1998; 5: 205-8.
56. FURUSYO N, HAYASHI J, UENO K, et al. Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis. Clin Ther 1997; 19: 1352-67.
57. FARRELL G, COOKSLEY W G, DUDLEY F J, WATSON K. Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group. J Viral Hepat 1997; 4: 317-23.
58. CAPORASO N, SUOZZO R, MORISCO F, D'ANTONIO M, ROMANO M, COLTORTI M. Recombinant human interferon alpha-2a therapy for chronic hepatitis C with or without cirrhosis. comparison of 3 or 6 MU for 1 year. Ital J Gastroenterol 1993; 25: 482-6.
59. DRUG TOPICS. Red Book. Medical Economics Co Inc., Montaville, NJ, 2000.
60. ST. ANTHONY'S D R G, GUIDEBOOK. ALEXANDRIA V A. St. Anthony Publishing, 2001.
61. WASSERMAN Y. Physician's Fee Reference 1995. West Allis: WI. Medical Publishers, 1995.
62. Physicians' Medicare Guide. CCHInc., Riverwoods, IL, 2001.
63. BROWN D M, EVERHART J E. Cost of Digestive Diseases in the United States. In: EVERHART J E, eds. Digestive Diseases in the United States. U.S. Department of Health and Human Services, Public Health Service, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1994.
64. EVANS R W. Liver transplantation in a managed care environment. Liver Transplantation Surg 1995; 1: 61-75.
65. SIEGEL J E, WEINSTEIN M C, RUSSELL L B, GOLD M R. Recommendations for reporting cost-effectiveness analysis. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1339-41.
66. KAPLAN E L, MEIER P. Nonparametric estimation for incomplete observation. J Am Stat Assoc 1958; 53: 457-81.
67. GREENWOOD M. The errors of sampling of the survivorship tables. Report on Public Health and Statistical Subjects 1926: 33: Appendix 1. HMSO.
68. WONG J B, SONNENBERG F A, SALEM D N, PAUKER S G. Myocardial revascularization for chronic stable angina. Analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989. Ann Intern Med 1990; 113: 852-71.
69. LINDOFORS K K, ROSENQUIST C J. The cost-effectiveness of mammographic screening strategies. JAMA 1995; 274: 881-4.
70. KOTOH K, SAKAI H, SAKAMOTO S, et al. The effect of percutaneous ethanol injection therapy on small solitary hepatocellular carcinoma is comparable to that of hepatectomy. Am J Gastroenterol 1994; 89: 194-8.
71. ARII S, YAMAOKA Y, FUTAGAWA S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group Japan Hepatol 2000; 32: 1224-9.
72. HOSHIDA Y, SHIRATORI Y, OMATA M. Difficulties in conducting controlled trials in radical therapies for nonadvanced hepatocellular carcinoma. Hepatology 2000; 32: 877-80.
73. ZEUZEM S, FEINMAN S V, RASENACK J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-72.
74. REDDY K R, WRIGHT T L, POCKROS P J, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433-8.
75. TARAO K, RINO Y, OHKAWA S, et al. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer 1999; 86: 589-95.
76. MORIYA K, FUJIE H, SHINTANI Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4: 1065-7.
77. TAYLOR D R, SHI S T, ROMANO P R, BARBER G N, LAI M M. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999; 285: 107-10.
78. KATO N, YOSHIDA H, KIOKO ONO-NITA S, et al. Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. Hepatology 2000; 32: 405-12.